What's in Centre Francois Baclesse's pipeline?

Centre Francois Baclesse has 10 drugs in our index: 5 marketed, 0 filed, 4 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Centre Francois Baclesse's portfolio?

Top competitors by shared drug class: American Regent, Inc., Daryoush Hamidi Alamdari, PhD, Federico II University, SolasCure Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centre-francois-baclesse.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Centre Francois Baclesse — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centre Francois Baclesse pipeline: 5 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 4 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis	Hematology/Oncology
Essential oils	Essential oils	marketed
ARM C : single epoietin zeta	ARM C : single epoietin zeta	marketed
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis	Hematology/Oncology
cabozantinib and nivolumab	cabozantinib and nivolumab	marketed
Hormonotherapy	Hormonotherapy	phase 3			Other
CHEMOTHERAPY ONLY	CHEMOTHERAPY ONLY	phase 3			Oncology
Ialuset®	Ialuset®	phase 3	Wound healing agent		Dermatology / Wound Care
Systematic RAI-treatment	Systematic RAI-treatment	phase 3		Thyroid cells	Oncology

Therapeutic area mix

Hematology/Oncology · 2
Oncology · 2
Dermatology / Wound Care · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

American Regent, Inc. · 1 shared drug class
Daryoush Hamidi Alamdari, PhD · 1 shared drug class
Federico II University · 1 shared drug class
SolasCure Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre Francois Baclesse:

Cite this brief

Drug Landscape (2026). Centre Francois Baclesse — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-francois-baclesse. Accessed 2026-06-10.